The present disclosure relates to methods of analyzing and authenticating a sample from a subject. Benefits of the methods disclosed herein can include the detection of multiple analytes in a whole blood sample, and the quantitative measurement of amounts of multiple drugs, or their metabolites, present in a single low volume whole blood sample. A benefit of the methods disclosed herein can include a combination of analyzing drugs or metabolites in a blood sample, and authenticating the blood sample, or a body sample, as being taken from the subject. Additional benefits of the methods herein can be safe, secure, accurate, and reliable authentication of blood samples and other body samples from a subject.

The present disclosure relates to methods of analyzing and authenticating a sample from a subject. Benefits of the methods disclosed herein can include the detection of multiple analytes in a whole blood sample, and the quantitative measurement of amounts of multiple drugs, or their metabolites, present in a single low volume whole blood sample. A benefit of the methods disclosed herein can include a combination of analyzing drugs or metabolites in a blood sample, and authenticating the blood sample, or a body sample, as being taken from the subject. Additional benefits of the methods herein can be safe, secure, accurate, and reliable authentication of blood samples and other body samples from a subject.

The present disclosure is directed to methods reagents and kits for solid phase extraction, derivatization with crown ether containing derivatizing agents, and mass spectrometry of the derivatized analytes.

It is an object of the present invention to provide an RNA aptamer that specifically binds histamine. The present invention is related to an nucleic acid aptamer that binds to histamine, comprising the base sequence (i) or (ii) below: (i) the base sequence of SEQ ID NO: 1; (ii) the base sequence comprising substitution(s), deletion(s), and/or addition(s) of 1 to 3 base(s) in the base sequence of SEQ ID NO: 1.

Compositions of matter, methods, devices, systems and apparatus for detecting analytes are disclosed including, for example, protein switches and their use in an in vivo sensor. The protein switch can be used to determine a level of an analyte that is diagnostic for health and/or well-being of a subject.

Compositions of matter, methods, devices, systems and apparatus for detecting analytes are disclosed including, for example, protein switches and their use in an in vivo sensor. The protein switch can be used to determine a level of an analyte that is diagnostic for health and/or well-being of a subject.

The disclosure is directed to a polyclonal antibody composition comprising a heterologous population of mammalian antibodies capable of specifically binding to tenofovir or a tenofovir derivative in a sample. Methods and assays for detecting tenofovir or a tenofovir derivative in a sample using the polyclonal antibody composition also are provided.

The disclosure is directed to a polyclonal antibody composition comprising a heterologous population of mammalian antibodies capable of specifically binding to tenofovir or a tenofovir derivative in a sample. Methods and assays for detecting tenofovir or a tenofovir derivative in a sample using the polyclonal antibody composition also are provided.

Among the various aspects of the present disclosure is the provision of molecular sensors, microbial sensors, constructs, systems, and methods for selectively detecting aromatic compounds.

The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.